Board of Directors & Advisors
Dr. Miri Halperin Wernli PhD, MBA
Group CEO, Co–Founder and Executive Director
Dr. Halperin Wernli is a senior pharma executive with over 25 years of strategic and operational leadership in global drug and product development in the pharmaceutical and biomedical industries. She held worldwide executive leadership positions in R&D and in strategic marketing within global pharmaceutical companies in Switzerland and in the US.
Boaz Wachtel M.A. Management and Marketing
Non-Executive Chairman and Co-Founder
Mr. Wachtel is a leading Medical cannabis expert, co-founder and former managing director of Phytotech Medical (MMJ.ASX), Australia's first publically traded medical cannabis company. He initiated and helped implement the National Medical Cannabis Program in Israel. Mr. Wachtel is a certified Clinical research manager and holds an MA in management and marketing from the University of Maryland.
Adam Blumenthal B.Com, MIR, MBA
Non-Executive Director and Co – Founder
Mr. Blumenthal has 10 years experience in investment banking and corporate finance. He has deep exposure to Australian and International markets, having provided capital raising and financing solutions to an extensive number of listed and unlisted companies. He has successfully brought to market several medical cannabis companies spanning Israel, Canada, Switzerland and Australia.
Chief Operating Officer
John Griese is an expert in cannabis and food manufacturing and supply chain. John has 30 years experience in executive operations roles with Pepsi and Nestle and more recently developed Cannabis experience as COO of Bloom Farms a large branded manufacturer and distributor in the California regulated market.
Dr. James Ellingford DMgt, MBA,
Post Grad Corp Man, AICD Non-Executive Director
Dr. Ellingford’s professional life culminated in being President of an international publicly listed billion dollar business with its headquarters in Geneva, Switzerland and New York, USA. He has vast experience in the international arena and has successfully developed close ties with both financial institutions as well as governments throughout the world.
Dr. Isaac Kobrin
Scientific Industry Advisor, MD
Dr. Isaac Kobrin is an internist with 15 years experience in the academic medicine both in Israel and the USA. He has over 22 years of experience in the Pharma Industry in Roche and Actelion. He has been responsible for the worldwide development of key compounds and has held numerous leadership positions in medical organisations.
Dr. Stéphane Redey
Scientific Industry Advisor, PhD
Dr. Stéphane Redey has over 18 years experience leading teams in the technical development of innovative drugs and strategic outsourcing. He has held senior positions with global responsibilities in pharmaceutical companies in both Switzerland and Australia. He has led successful international collaborations with companies on four continents.
Dr. Raquel Peyraube
Scientific Industry Advisor, MD
Dr. Raquel Peyraube is a specialist in the drug field with more than 28 years experience. Throughout her career she has been involved in training, prevention, treatment and harm reduction, developing innovative approaches emphasising ethical issues which has earned her international recognition. Dr Peyraube is currently a consultant on drug policy reform in Latin America.
Prof. Dr. med Felix Gutzwiller
Scientific Industry Advisor, MD, MPH, PhD
Felix Gutzwiller holds the titles of MD of the University of Basel, an MPH of the Harvard School of Public Health, Dr. PH of the Johns Hopkins University School of Hygiene and Public Health. He was a Professor at the University of Basel and a Professor of Social and Preventive Medicine at the University of Zürich (1988-2013), Emeritus since 2013.
Dr. Gian Trepp ETH/MBA/IMD
Dr. Gian Trepp is a senior pharma marketing executive with over 18 years of strategic and operational leadership. He held worldwide executive leadership positions in General Management and Marketing within global pharmaceutical companies in Switzerland and in the US. He is the founder and owner of GBT Pharma, UK.
Jorge Wernli ETH/MBA/IMD
Mr Wernli is an expert in Market Access, Pricing Reimbursement & Government Affairs with more than 30 years of experience in Big Pharmaceutical companies and start-ups. Previously he dealt with and built relationships with Ministries of Health in Europe, South America and selected Asian countries.
Prof. Dr. Walter P. von Wartburg
Prof. Dr. Walter P von Wartburg, Dr.iur., Attorney at Law, LL.M. (Harvard) is an internationally very experienced lawyer in the areas of Health and Communication/PR, Since over 20 years he is Partner, „Law & Life Sciences“ Consultancy, providing legal, communication and issues management advice to biotech based Life Sciences businesses. He held several executive positions at Novartis, Ciba-Geigy and Roche over 20 years.